Published online August 14, 2007
PEDIATRICS Vol. 120 No. 3 September 2007, pp. e622-e628 (doi:10.1542/peds.2006-3164)

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mahlaoui, N. Articles by Fischer, A. Search for Related Content PubMed PubMed Citation Articles by Mahlaoui, N. Articles by Fischer, A. Related Collections Infectious Disease & Immunity Social Bookmarking                         What's this?

ARTICLE

Immunotherapy of Familial Hemophagocytic Lymphohistiocytosis With Antithymocyte Globulins: A Single-Center Retrospective Report of 38 Patients

Nizar Mahlaoui, MD^a, Marie Ouachée-Chardin, MD^a, Geneviève de Saint Basile, MD, PhD^b, Bénédicte Neven, MD^a, Capucine Picard, MD, PhD^a, Stéphane Blanche, MD^a and Alain Fischer, MD, PhD^a,b

^a Unité d'Immunologie et Hématologie Pédiatrique, Assistance Publique–Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
^b Université Descartes, INSERM U768, Paris, France

OBJECTIVES. Familial hemophagocytic lymphohistiocytosis is a genetically determined condition that is characterized by unremitting CD8 T lymphocyte and macrophage activation and leads to death in the absence of therapy. On the basis of the immunologic pathophysiology of familial hemophagocytic lymphohistiocytosis, we propose a therapy with a combination of antithymocyte globulins with corticosteroids, cyclosporin A, and intrathecal injections of methotrexate.

METHODS. We retrospectively analyzed the outcome of antithymocyte globulin–based therapy that was performed in 38 consecutive patients who had familial hemophagocytic lymphohistiocytosis and were treated in a single center between 1991 and 2005. Overall, they received 45 courses of antithymocyte globulin (5–10 mg/kg per day for 5 days).

RESULTS. This regimen was associated with infections after 10 of 45 courses of antithymocyte globulin. There were 6 events after 11 antithymocyte globulin courses given as second-line therapy against 4 after 34 antithymocyte globulin courses in patients who were treated primarily with antithymocyte globulin. Antithymocyte globulin administration led to rapid and complete response of familial hemophagocytic lymphohistiocytosis in 73% of cases, partial response in 24%, and no response only once. When hematopoietic stem cell transplantation was performed early after complete or partial response induction, it led to a high rate of cure, in 16 of 19 cases. Overall survival was 21 of 38 with 4 toxic deaths.

CONCLUSION. Antithymocyte globulin based immunotherapy of familial hemophagocytic lymphohistiocytosis is efficient and carries an acceptable toxicity when used as a first treatment of familial hemophagocytic lymphohistiocytosis.

---

Key Words: antithymocyte globulins • familial hemophagocytic lymphohistiocytosis • immunotherapy • complete response

Abbreviations: FHLH—familial hemophagocytic lymphohistiocytosis • CNS—central nervous system • HSCT—hematopoietic stem cell transplantation • ATG—antithymocyte globulin • CR—complete response • PR—partial response • EBV-BLPD—Epstein-Barr virus–induced B cell lymphoproliferative disease

---

Accepted Jan 29, 2007.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Pachlopnik Schmid, D. Moshous, N. Boddaert, B. Neven, L. Dal Cortivo, M. Tardieu, M. Cavazzana-Calvo, S. Blanche, G. de Saint Basile, and A. Fischer Hematopoietic stem cell transplantation in Griscelli syndrome type 2: a single-center report on 10 patients Blood, July 2, 2009; 114(1): 211 - 218. [Abstract] [Full Text] [PDF]